Tag: renal denervation
DeepQure advances clinical trials of its HyperQure extravascular renal denervation system
DeepQure has announced progress of clinical trials of its extravascular renal denervation device...
Boston Scientific to acquire renal denervation technology developer SoniVie
Boston Scientific has entered into a definitive agreement to acquire SoniVie Ltd, a privately he...
CMS launches review of coverage for renal denervation
The Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (...
Attention turns to multi-organ denervation as new evidence supports “durability” of blood pressure reductions
New research will investigate the safety and efficacy of multi-organ, hepatic artery and renal a...
CMS grants transitional pass-through payment for Medtronic’s Symplicity Spyral and Recor’s Paradise renal denervation systems
The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through (TPT) pay...
TCT 2024: Two-year SPYRAL HTN-ON MED show “consistent” effect of renal denervation
Medtronic has announced new, long-term data from the SPYRAL HTN-ON MED clinical trial that showe...
Renal denervation gains class IIb recommendation in ESC guidelines
Latest guidelines from the European Society of Cardiology (ESC) on the management of blood press...
ESC hypertension guidelines stipulate conditions for renal denervation use
ESC guidelines on the management of elevated blood pressure and hypertension include recommendations...
Money-maker or meritable: Is renal denervation out of retirement?
In a paper published in the July 2024 issue of the Journal of Hypertension, Andrew Sharp (University...
First patients treated in US GPS study of Paradise renal denervation system
The first patients in the USA have been treated in Recor Medical’s Global Paradise System US Pos...
SoniVie announces advancements in its renal denervation programme
SoniVie, which has developed a novel Therapeutic Intra-Vascular Ultrasound System (TIVUS) to treat a...
DeepQure receives IDE approval of extravascular renal denervation system to treat resistant hypertension
DeepQure, a Seoul based medical device company with a novel, extravascular solution for renal de...
Study of TIVUS renal denervation system for hypertension treatment completes enrolment
The REDUCED-1 study, a US Food and Drug Administration (FDA) investigational device exemption (IDE)-...
SCAI: First US renal denervation approvals “revolutionise” treatment of uncontrolled hypertension
The approval of two renal denervation devices by the US Food and Drug Administration (FDA)—the Parad...
Medtronic’s Symplicity Spyral renal denervation system granted US FDA approval for hypertension treatment
Medtronic has announced approval from the US Food and Drug Administration (FDA) for the Symplicity S...
Recor Medical gains first US FDA renal denervation approval
Recor Medical has become the first company in the USA to have a device-based therapy approved fo...
SCAI: FDA panel vote “encouraging” for advance of renal denervation
The Society for Cardiovascular Angiography & Interventions (SCAI) has welcomed the review of sci...
FDA panel split on risk and benefit of Symplicity Spyral renal denervation system
The US Food and Drug Administration (FDA) Circulatory Systems Devices Panel met yesterday (23 Au...
FDA panel votes favourably on safety and efficacy of Paradise renal denervation system
The US Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices A...
Sham-controlled trials prompt renal denervation hypertension guideline update
Latest research in the field of renal denervation has prompted its inclusion in updated guidelin...
ESH guidelines represent a “significant milestone” for hypertension management
ReCor Medical and its parent company Otsuka Medical Devices have welcomed the release of updated...
Patient advocacy group says ESH guideline change will improve access to renal denervation
Citizens of Europe at risk for heart attacks, stroke and chronic kidney disease due to uncontrolled ...
New arterial hypertension guidelines update recommendations on the use of renal denervation
New and expanded guidelines from the European Society of Hypertension (ESH) concerning the managemen...
Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial
A new trial of endovascular ultrasound-based renal denervation technology has found that it redu...
Results on ReCor Medical’s Paradise ultrasound renal denervation system published in two JAMA Network publications
ReCor Medical and its parent company, Otsuka Medical Devices, recently announced that primary en...
Medtronic welcomes ESC and EAPCI renal denervation consensus statement
Medtronic has welcomed the publication of the consensus statement on renal denervation issued by the...
Renal denervation “can reach new shores”
The publication of a consensus statement from the European Society of Cardiology (ESC) Council o...
ESC and EAPCI publish renal denervation consensus statement
Renal denervation represents another treatment option in patients with uncontrolled resistant hypert...
ReCor appoints Lara Barghout to lead commercialisation of Paradise renal denervation system
ReCor Medical and its parent company Otsuka Medical Devices have announced the appointment of La...
Otsuka Medical Devices and ReCor Medical submit pre-market approval of Paradise ultrasound renal denervation system
Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing ...
ReCor Medical announces consistent reduction of blood pressure in pooled analysis of three clinical trials at AHA 2022
ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significa...
AHA 2022: SPYRAL HTN-ON MED study demonstrates “meaningful clinical benefits” consistent with other renal denervation trials
Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clin...
Latest data underscore optimism for future of renal denervation
Ajay Kirtane (Columbia University Irving Medical Center New York-Presbyterian Hospital, New York...
TCT 2022 hears “important data” from renal denervation trials
Findings from the RADIANCE II randomised pivotal trial, presented at the 2022 Transcatheter Card...
Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study
ReCor Medical and Otsuka Medical Devices have announced that the RADIANCE II US Food and Drug Admini...
SoniVie receives FDA IDE approval for pilot study to treat hypertension with renal artery denervation TIVUS technology
SoniVie recently announced that on 5 May 2022 the US Food and Drug Administration (FDA) granted inve...
New consensus statement will take into account latest clinical trial evidence on renal denervation
A new consensus statement—in development from the European Society of Cardiology (ESC) and the ...
EuroPCR 2022: Sham controlled trials have “revitalised” interest in renal denervation
“Renal denervation has travelled a very storied path over the last 10–15 years,” David Kandzari...
EuroPCR 2022: Studies underscore potential of renal denervation as an adjunctive therapy for hypertension
Late-breaking trial data presented at EuroPCR 2022 (17–20 May, Paris, France) underscore the pot...
ACC.22: Three-year data show “durable blood pressure reductions” through renal denervation
Long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial have been presented during ...
RADIANCE-II renal denervation trial completes enrolment
Investigators have completed enrolment in the RADIANCE-II pivotal trial of the Paradise ultrasound r...
SyMap Medical closes US$100 million financing round
SyMap Medical has announced the completion of a financing round which will be used to accelerate...
TCT 2021: Randomised trials show “consistent” reduction in blood pressure through renal denervation
Randomised placebo-controlled trials show consistently that renal denervation provides significant r...
TCT 2021: Six-month RADIANCE-HTN TRIO results “open a window” for renal denervation
Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasoun...
TCT 2021: Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study
Medtronic has announced findings from a new study of patient preferences for the treatment of hypert...
ReCor Medical’s Paradise ultrasound renal denervation system used in first German cases
ReCor Medical has announced that its Paradise ultrasound renal denervation system is now available f...
Renal denervation: The most advanced and efficacious interventional approach to treat hypertension
Following the release of the European Society of Hypertension’s (ESH’s) updated position paper o...
ESH position paper highlights renal denervation as a third option for hypertension management
European Society of Hypertension (ESH), the leading hypertension (HTN) society in Europe, presented ...
EuroPCR 2021: Late-breaking data demonstrate long-term benefits of Medtronic radiofrequency renal denervation in real-world hypertensive patients
Medtronic today announced new clinical data from the Global SYMPLICITY registry (GSR) indicating...
PCR e-Course 2020: Sham patients from RADIANCE-HTN SOLO who crossed over to denervation had reduced blood pressure
Patients who crossed over from the sham control arm of the RADIANCE-HTN SOLO trial to the renal ...
Virtual ACC: Renal denervation bests sham control to safely lower blood pressure in patients with untreated hypertension
Three months after undergoing renal denervation, patients with untreated high blood pressure had...
Renal denervation still holds strong potential as a therapy for hypertension
Although renal denervation may not hit the heights originally envisaged for it in the management of ...
TARGET BP I trial enrols its first patient
The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute i...
EuroPCR 2019: Renal denervation linked to reduction in subclinical atrial fibrillation
Data presented at EuroPCR today indicates that renal denervation with the Symplicity system (Med...
RADIANCE SOLO HTN finds greater blood pressure drop after renal denervation
Six-month "on-medication" results from the RADIANCE-HTN SOLO clinical trial have found that patients...
CRT 2019: Renal denervation using alcohol “seems very effective”
The renal denervation bubble collapsed due to a single trial—SYMPLICITY HTN-3, but this trial’s...
CRT 2019: Redesigning the resurgence of renal denervation
David Kandzari (Atlanta, USA) tells Cardiovascular News at CRT 2019 that renal denervation is typ...
The resurgence of renal denervation
More than ever before, arterial hypertension represents one of the greatest health threats and c...
US FDA approve new study of Medtronic’s Spyral renal denervation system
The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyra...
Otsuka Medical Devices, Otsuak Holdings, and ReCor Medical to merge
Otsuka Holdings, Otsuka Medical Devices, and ReCor Medical have signed a merger agreement pursua...
FDA approves RADIANCE-II study of Paradise ultrasound denervation system
The RADIANCE-II study of the Paradise Ultrasound Denervation System (ReCor Medical) for the trea...
EuroPCR 2018: Will SPYRAL-ON change my practice?
In this PCR video, David E Kandzari (Department of Interventional Cardiology, Piedmont Heart Institu...
EuroPCR 2018: Positive data for renal denervation reignites interest in field
After two studies indicated that renal denervation lowers blood pressure both with and without a...
New trial of Symplicity Spyral approved
Medtronic has announced US FDA approval to begin an investigational device exemption (IDE) pivot...
From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal denervation
It is now almost a decade since the first patient underwent catheter-based renal denervation as ...
ESC 2017: MobiusHD implant shown to reduce resistant hypertension
The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate...
ESC 2017: SPYRAL HTN-OFF MED provides “proof of principle” that renal denervation works
Results from SPYRAL HTN-OFF MED indicate that renal denervation, compared with a sham procedure,...
Renal denervation devices are alternatives to drug therapy, Technavio reports
Analysts from Technavio have forecast the global renal denervation market to grow at a compound annu...
